Group by:
Item Type |
DateNumber of items: 4.
Journal article
Simpson, E. L.; Lacour, J.-P.; Spelman, L.; Galimberti, R.; Eichenfield, L. F.; Bissonnette, R.; King, B. A.; Thyssen, J. P.; Silverberg, J. I.; Bieber, T.; Kabashima, K.; Tsunemi, Y.; Costanzo, A.; Guttman-Yassky, E.; Beck, L. A.; Janes, J. M.; DeLozier, A. M.; Gamalo, M.; Brinker, D. R.; Cardillo, T.; Nunes, F. P.; Paller, A. S.; Wollenberg, A. und Reich, K.
(2020):
Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phaseIIItrials.
In: British Journal of Dermatology, Vol. 183, No. 2: pp. 242-255
Silverberg, J. I.; Thyssen, J. P.; Paller, A. S.; Drucker, A. M.; Wollenberg, A.; Lee, K. H.; Kabashima, K.; Todd, G.; Schmid-Grendelmeier, P. und Bieber, T.
(2017):
What's in a name? Atopic dermatitis or atopic eczema, but not eczema alone.
In: Allergy, Vol. 72, No. 12: pp. 2026-2030
Nemoto, O.; Furue, M.; Nakagawa, H.; Shiramoto, M.; Hanada, R.; Matsuki, S.; Imayama, S.; Kato, M.; Hasebe, I.; Taira, K.; Yamamoto, M.; Mihara, R.; Kabashima, K.; Ruzicka, T.; Hanifin, J. und Kumagai, Y.
(2016):
The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study.
In: British Journal of Dermatology, Vol. 174, No. 2: pp. 296-304
This list was generated on Sun Dec 1 03:40:24 2024 CET.